Réalisées par des traducteurs professionnels, des entreprises, des pages web ou traductions disponibles gratuitement.
tranexamic acid
traneksamska kiselina
Dernière mise à jour : 2017-04-26
Fréquence d'utilisation : 1
Qualité :
there is limited experience with tranexamic acid and no experience with aminocaproic acid and aprotinin in individuals receiving rivaroxaban.
iskustvo s primjenom aminokaproatne kiseline je ograničeno te nema iskustva s primjenom traneksamatne kiseline i aprotinina u bolesnika koji primaju rivaroksaban.
there is no experience with antifibrinolytic agents (tranexamic acid, aminocaproic acid) in individuals receiving edoxaban.
nema iskustva s primjenom antifibrinolitika (traneksamatne kiseline, aminokaproatne kiseline) u osoba koje primaju edoksaban.
antifibrinolytic therapy (aminocaproic acid or tranexamic acid) and/or recombinant factor viia therapy may increase haemostasis.
antifibrinolitička terapija (aminokaproična i traneksamična kiselina) i/ili terapija rekombinantnim faktorom viia mogu povećati hemostazu.
there is limited experience of using novoseven together with medicines called antifibrinolytic drugs (such as aminocaproic acid or tranexamic acid) which are also used to control bleeding.
ograničeno je iskustvo primjene lijeka novoseven zajedno s lijekovima koji se zovu antifibrinolitički lijekovi (kao što su aminokaproatna kiselina ili traneksamatna kiselina) koji se također koriste za kontrolu krvarenja.
however, the concomitant use of another type of fibrin glue with a synthetic fibrinolysis inhibitor (tranexamic acid) in the pivotal clinical trial did not reveal any safety signal.
ipak, upotreba druge vrste fibrinskog ljepila sa sintetičkim inhibitorom fibrinolize (traneksamska kiselina) u pivotalnom ispitivanju nije otkrila nikakav sigurnosni signal.
eleven subjects were reported to have received anti-haemorrhagic agents (eg. rfviia, activated prothrombin-complex concentrate, tranexamic acid) prior to first treatment with obizur.
u jedanaest ispitanika zabilježeno je uzimanje lijekova protiv krvarenja (primjerice rfviia, aktivirani koncentrat protrombinskog kompleksa, traneksamična kiselina) prije prvog liječenja lijekom obizur.
phase iii clinical studies (fast-1 and fast-2) were randomized, double-blind, controlled trials and had identical designs except for the comparator (one with oral tranexamic acid as the comparator and one placebo controlled).
klinička ispitivanja faze iii (fast-1 i fast-2) bila su randomizirana, dvostruko slijepa, kontrolirana ispitivanja s identičnim dizajnom, osim u slučaju komparatora (jedno je kao komparator imalo peroralno primijenjenu traneksamsku kiselinu, a drugo je bilo kontrolirano placebom).